Promotes the production of short-chain fatty acids in the intestines
Red yeast rice products effectively enhance short-chain fatty acid production in the intestines, improving intestinal health and systemic signaling, addressing pathogenic infections and metabolic regulation.
Patent Information
- Application Number
- JP2020196382
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-11-26
- Publication Date
- 2024-11-21
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need to enhance the production of short-chain fatty acids in the intestines to increase signal transduction and systemic signaling through these receptors, which can prevent pathogenic bacterial infections, improve allergic inflammation, and regulate metabolic functions.
The use of red yeast rice or its processed products, particularly those produced using Monascus pilosus, to promote the production of short-chain fatty acids such as lactic acid, succinic acid, and butyric acid in the intestine.
The promotion of short-chain fatty acid production strengthens the intestinal barrier function, enhances signal transmission via GPR41, GPR43, and other receptors, improving biological homeostasis and regulating insulin secretion, thereby preventing and treating related symptoms and diseases.
Smart Images

Figure 0007587971000001 
Figure 0007587971000002 
Figure 0007587971000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a short-chain fatty acid production promoter that effectively promotes the production of short-chain fatty acids in the intestine. [Background technology]
[0002] As a result of indigestible foods and polysaccharides derived from diet being assimilated by intestinal bacteria, short-chain fatty acids such as propionic acid, butyric acid, and succinic acid are produced as metabolic products. Conventionally, it has been thought that short-chain fatty acids produced in the intestine are used as an energy source for the host, but in recent years, it has been revealed that they also contribute to the prevention of pathogenic bacteria infection and the improvement of allergic inflammation by enhancing the intestinal barrier function. Furthermore, it has recently been elucidated that short-chain fatty acids produced in the intestine also act as signal molecules mediated by G protein-coupled receptors (GPCRs), and GPR41, GPR43, GPR91, GPR109a, and Olfr78 have been identified as short-chain fatty acid receptors (see Non-Patent Documents 1 to 3).
[0003] In addition, various biological regulation functions of short-chain fatty acid receptors have been elucidated. Among the short-chain fatty acid receptors, GPR41 and GPR43 are known to have a very high affinity for short-chain fatty acids and to express signal transduction even at low concentrations, and have been reported to be involved in the promotion of secretion of PYY (peptide YY) and GLP-1 (glucagon-like peptide-1) in the intestine, and the control of insulin secretion in the pancreas. In addition, it has been reported that GPR43, which is expressed in sympathetic ganglia by short-chain fatty acids, activates sympathetic nerves and promotes the secretion of noradrenaline (Non-Patent Document 4).
[0004] As such, short-chain fatty acid receptors have various biological regulatory functions, and enhancing signal transduction via short-chain fatty acid receptors is effective not only for maintaining health, but also for treating symptoms and diseases that can be prevented, treated, or improved by enhancing signal transduction via short-chain fatty acid receptors. [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] I Kimura et al., The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nature Communications. 4, 1829, 2013. [Non-Patent Document 2] Ikuo Kimura, Functional analysis of fatty acid receptors for drug discovery applications: Pharmacia. 50, 867-868, 2014. [Non-Patent Document 3] Junki Miyamoto et al., Fatty acid metabolism and intestinal environment: Anti-aging Medicine 14:030-035,2018 [Non-Patent Document 4] Miyamoto J et al., Nutritional Signaling via Free Acid Receptors. Int J Mol Sci. 17, 450, 2016. Summary of the Invention [Problem to be solved by the invention]
[0006] Increasing the amount of short-chain fatty acid produced in the intestine not only enhances signal transduction via short-chain fatty acid receptors in the intestine, but also increases the amount of short-chain fatty acid transferred into the blood, which can lead to enhancement of signal transduction via short-chain fatty acid receptors throughout the body. Therefore, the present invention aims to provide a short-chain fatty acid production promoter that effectively promotes the production of short-chain fatty acids in the intestine. [Means for solving the problem]
[0007] The present inventors conducted extensive research to solve the above problems and found that red koji or a processed product thereof has the effect of effectively promoting the production of short-chain fatty acids in the intestines. The present invention was completed through further research based on this finding.
[0008] That is, the present invention provides the following aspects. Item 1. An agent for promoting the production of short-chain fatty acids in the intestines, which contains red koji or a processed product thereof. Item 2. The short-chain fatty acid production promoter according to Item 1, wherein the red koji or a processed product thereof is produced using Monascus pilosus. Item 3. The short-chain fatty acid production promoter according to Item 1 or 2, which is used to promote production in the intestine of at least one short-chain fatty acid selected from the group consisting of lactic acid, succinic acid, and butyric acid. Item 4. The short-chain fatty acid production promoter according to any one of Items 1 to 3, which is used by being added to a food or drink, an internal medicine, an animal feed, or a pet food. Item 5. A method for promoting intestinal production of short-chain fatty acids, comprising the step of having a person in need of promotion of intestinal production of short-chain fatty acids ingest red koji or a processed product thereof. Item 6. Use of red koji or a processed product thereof for the manufacture of an agent for promoting the production of short-chain fatty acids in the intestine. Item 7. Red yeast rice or its processed products used to promote the production of short-chain fatty acids in the intestines. Item 8. Non-therapeutic use of red yeast rice or a processed product thereof for promoting the production of short-chain fatty acids in the intestine. Effect of the Invention
[0009] The short-chain fatty acid production promoter of the present invention can promote the production of short-chain fatty acids, which are metabolic products of intestinal bacteria, in the intestine. The short-chain fatty acid production promoter of the present invention can be expected to have effects such as prevention of pathogen infection by enhancing intestinal barrier function and improvement of allergic inflammation by increasing the amount of short-chain fatty acids produced in the intestine. In addition, the short-chain fatty acid production promoter of the present invention can enhance signal transduction via short-chain fatty acid receptors by increasing the amount of short-chain fatty acids produced in the intestine, and can therefore be expected to have effects such as improvement of homeostasis function, promotion of secretion of PYY and GLP-1, regulation of insulin secretion, activation of sympathetic nerves, and prevention, treatment, or improvement of symptoms and diseases in which signal transduction via short-chain fatty acid receptors is reduced. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] The short-chain fatty acid production promoter of the present invention is used to promote the production of short-chain fatty acids in the intestine, and is characterized by containing red koji or a processed product thereof. The short-chain fatty acid production promoter of the present invention will be described in detail below.
[0011] [Definition] As used herein, the term "short-chain fatty acid production promoter" refers to an agent used to promote the production of short-chain fatty acids in the intestine.
[0012] [Red yeast rice or its processed products] The short-chain fatty acid production promoter of the present invention contains red koji or a processed product thereof as an active ingredient. Red koji is koji made by fermenting cereals with red koji mold.
[0013] The Red Koji mold used in the present invention for producing the Red Koji may be any filamentous fungus belonging to the Monascaceae family. Examples of the filamentous fungus belonging to the Monascaceae family include filamentous fungi belonging to the genera Monascus and Basipetospora, and preferably the genus Monascus.
[0014] Examples of filamentous fungi belonging to the genus Monascus include Monascus pilosus, Monascus purpureus, Monascus pubigerus, Monascus anka, Monascus serorubescens, Monascus rubellus, Monascus kaoliang, Monascus rubiginosus, Monascus major, Monascus ruber, Monascus paxii, Monascus fuliginosus, Monascus vitreus, Monascus barkeri, Monascus valeri ... barkeri, Monascus sp., and variants or mutants thereof. The red koji used in the present invention may be produced using one type of red koji fungus, or may be produced by combining two or more types of red koji fungus. Among these red koji fungus fungi, Monascus pilosus is preferred from the viewpoint of exerting a more excellent effect of promoting the production of short-chain fatty acids.
[0015] The type of grain used as the raw material for the red koji used in the present invention is not particularly limited, as long as it is edible and can be fermented by Red Koji mold, and examples thereof include rice such as white rice and brown rice; wheat, barley, rye, oats, and other grains; soybeans (white soybeans, black soybeans, green soybeans, etc.), defatted soybeans, and legumes such as hypocotyls thereof. The red koji used in the present invention may be produced using one type of grain, or may be produced by combining two or more types of grains. Among these grains, rice is preferable, and white rice is more preferable.
[0016] Red koji can be produced by a conventional method using Red koji mold and grains. Specifically, Red koji can be produced by inoculating Red koji mold into grains that have been steamed (cooked or steamed) and allowing them to stand under aerobic conditions at about 20 to 40° C. Furthermore, the grains used as raw materials may be chopped or crushed as necessary before or after steaming.
[0017] In the present invention, the fermented red koji may be used as is, or a processed product of the fermented red koji may be used which has been subjected to one or more treatments including heating, drying, crushing, pulverization, grinding, extraction, etc.
[0018] Specific examples of processed red koji include dried products such as dried red koji, powdered dried red koji, fine granules of dried red koji, and red koji extract powder; red koji paste; and red koji extract (including concentrated extract). Among these processed red koji products, preferred are dried products, more preferred are powdered dried red koji, fine granules of dried red koji, and even more preferred are powdered dried red koji. The red koji fungus and enzymes contained in the processed red koji product may be live or may maintain their activity, or may be inactivated by heat treatment or the like.
[0019] The processed red koji can be a commercially available product. For example, powdered dried rice red koji is sold under the trade names "V. Red koji 3P-D" and "V. Red koji 3P-D20" (both manufactured by Kobayashi Value Support Co., Ltd.), and these commercially available products can be used in the present invention.
[0020] [Dosage form / form of use, etc.] The short-chain fatty acid production promoter of the present invention is provided in a desired dosage form by using the active ingredient red koji or a processed product thereof as is, or by combining it with other edible ingredients. The dosage form of the short-chain fatty acid production promoter of the present invention is not particularly limited, and may be any of solid, semi-solid, and liquid forms.
[0021] Since the short-chain fatty acid production promoter of the present invention is used for the purpose of promoting the production of short-chain fatty acids in the intestine, it may be in a form that allows it to be transported into the intestine, and preferably in a form that is ingested or administered orally, but may also be in a form that is administered enterally.
[0022] Specific examples of the use form of the short-chain fatty acid production promoter of the present invention include foods and beverages, internal medicines (including internal quasi-drugs), feed, pet food, etc. Among these, foods and beverages and internal medicines are preferred, and foods and beverages are more preferred.
[0023] When the short-chain fatty acid synthesis promoter of the present invention is used in food and drink (i.e., when it is provided as a food and drink for promoting the synthesis of short-chain fatty acids), red koji or a processed product thereof may be prepared into a desired form as is or in combination with other food and drink materials or additives. Examples of such food and drink include general food and drink, health functional foods (including foods for specified health uses, foods with nutritional functions, supplements, etc.), foods for sick people, etc. The form of these food and drink is not particularly limited, but specific examples include supplements such as capsules (soft capsules, hard capsules), tablets, granules, powders, and jellies; beverages such as tea drinks, nutritional drinks, fruit juice drinks, carbonated drinks, and lactic acid drinks; and luxury items such as gummies, candies, and jellies. Among these food and drink, supplements are preferred, and capsules, tablets, granules, and powders are more preferred.
[0024] When the short-chain fatty acid production promoter of the present invention is used in an internal medicine (including internal quasi-drugs), red koji or a processed product thereof may be prepared into a desired form either as is or in combination with other additives, etc. Specific examples of such internal medicines include tablets, pills, powders, fine granules, granules, capsules (including hard capsules and soft capsules), troches, chewables, drinks, extracts (including soft extracts, dry extracts, etc.), jellies, syrups, spirits, elixirs, liposome preparations, etc.
[0025] When the short-chain fatty acid production promoter of the present invention is used in feed or pet food, red koji or a processed product thereof may be prepared into a desired form either as is or in combination with other materials, additives, etc. Specific examples of feed include feeds fed to livestock such as cows, pigs, and sheep, and poultry such as chickens, quails, and ostriches. Specific examples of pet food include pet foods fed to dogs, cats, rabbits, hamsters, etc.
[0026] In the short-chain fatty acid production promoter of the present invention, the content of red koji or a processed product thereof may be appropriately determined based on the daily intake / administration amount of red koji or a processed product thereof, taking into consideration the subject's physique, age, symptoms, the level of short-chain fatty acid production in the intestine, the form of the short-chain fatty acid production promoter, etc., and may be, for example, 1 to 100% by weight.
[0027] [Application / Dosage] The short-chain fatty acid production promoter of the present invention is used for promoting the production of short-chain fatty acids in the intestine. In the present invention, the short-chain fatty acid is a short-chain fatty acid generated as a metabolic product of intestinal bacteria, and specifically includes short-chain fatty acids having 1 to 6 carbon atoms, such as lactic acid, succinic acid, butyric acid, isobutyric acid, acetic acid, propionic acid, formic acid, isovaleric acid, valeric acid, isocaproic acid, caproic acid, and pyruvic acid. The short-chain fatty acid production promoter of the present invention preferably includes short-chain fatty acids having 1 to 5 carbon atoms, more preferably short-chain fatty acids having 1 to 4 carbon atoms, and even more preferably, particularly preferably short-chain fatty acids having 2 to 4 carbon atoms. Among these short-chain fatty acids, the short-chain fatty acid production promoter of the present invention is particularly excellent in the effect of promoting the production of lactic acid, succinic acid, and butyric acid, and is therefore preferably used for promoting the production of at least one of lactic acid, succinic acid, and butyric acid.
[0028] Furthermore, increasing the production of short-chain fatty acids in the intestines enhances intestinal barrier function and is effective in preventing infection by pathogenic bacteria and improving allergic inflammation in the intestines, so the short-chain fatty acid production promoter of the present invention can be used for enhancing intestinal barrier function; preventing infection by pathogenic bacteria via the intestines; improving allergic inflammation in the intestines, etc.
[0029] In addition, since a high-fat diet leads to a decrease in the amount of short-chain fatty acids produced in the intestine, the short-chain fatty acid production promoter of the present invention can also be used to suppress the decrease in the amount of short-chain fatty acid produced due to the intake of a high-fat diet. Here, a high-fat diet is a food in which the proportion of fat in the total intake energy (fat weight ratio) is 30% or more.
[0030] In addition, the increase in the production of short-chain fatty acids in the intestine not only enhances signal transduction via short-chain fatty acid receptors in the intestine, but also increases the amount of short-chain fatty acids transferred into the blood, which can result in enhancement of signal transduction via short-chain fatty acid receptors throughout the body. Therefore, the short-chain fatty acid production promoter of the present invention can enjoy the effects based on enhancement of signal transduction via short-chain fatty acid receptors not only in the intestine but also in the entire body.
[0031] For example, enhanced signal transduction via short-chain fatty acid receptors (GPR41, GPR43, GPR91, GPR109a, and Olfr78) can result in enhanced homeostatic functions, and therefore the short-chain fatty acid production promoter of the present invention can be used for enhancing homeostatic functions; for preventing, treating, or improving symptoms or diseases in which reduced signal transduction via short-chain fatty acid receptors occurs; and the like.
[0032] Since enhanced signal transduction via GPR41 and GPR43 leads to promoted secretion of PYY and GLP-1 in the intestine, the short-chain fatty acid production promoter of the present invention can also be used for promoting PYY secretion in the intestine; preventing, treating or improving symptoms and diseases caused by reduced PYY secretion ability; promoting GLP-1 secretion in the intestine; and preventing, treating or improving symptoms and diseases caused by reduced GLP-1 secretion ability.
[0033] In addition, since signal transduction via GPR41 and GPR43 is also involved in the regulation of insulin secretion in the pancreas, the short-chain fatty acid production promoter of the present invention can also be used for regulating insulin secretion; for preventing, treating or ameliorating type 2 diabetes, etc.
[0034] Furthermore, since enhancement of signal transduction via GPR43 expressed in sympathetic ganglia activates the sympathetic nerves and promotes the secretion of noradrenaline, the short-chain fatty acid production promoter of the present invention can also be used for activating the sympathetic nerves; promoting the secretion of noradrenaline, etc.
[0035] In the short-chain fatty acid production promoter of the present invention, the daily intake / administration amount of red koji or a processed product thereof may be set according to the physique, age, symptoms, level of short-chain fatty acid production in the intestine of the subject, purpose of use of the short-chain fatty acid production promoter, etc., and may be set, for example, to about 100 to 60,000 mg, preferably about 200 to 30,000 mg, calculated as the dry weight of red koji. Here, "calculated as the dry weight of red koji" refers to the dry weight of unprocessed red koji when used, to the dry weight of red koji contained in the processed product when used as a processed product other than red koji extract and red koji extract powder, and to the dry weight of red koji used as the raw material for extracting red koji extract or red koji extract powder when used as a red koji extract or red koji extract powder.
[0036] Furthermore, the short-chain fatty acid production promoter of the present invention may be ingested or administered at a daily intake / administration amount once per day or divided into multiple doses per day, but it is preferable to ingest or administer it once or two to three times per day. EXAMPLES
[0037] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these.
[0038] Test Example 1. Test materials and methods 1-1. Processed products of red koji As a processed red koji product, we used powdered dried rice red koji (product name "V. Red koji 3P-D20", manufactured by Kobayashi Value Support Co., Ltd.) This powdered dried rice red koji is a dried powder of red koji made by fermenting white rice with Monascus pilosus, and the red koji fungus and enzymes are inactivated by heat treatment.
[0039] 1-2. Measurement of succinic acid and lactic acid production by intestinal bacteria Feces from a 10-week-old male mouse (C57BL / 6) was inoculated onto a GAM agar medium using modified GAM bouillon (Nissui Pharmaceutical Co., Ltd.) to culture the intestinal bacteria. Next, a platinum loopful of the intestinal bacteria cultured on the agar medium was inoculated into a test tube containing 3 ml of GAM liquid medium, and 1 ml of liquid paraffin was added to the top layer of the medium. The intestinal bacteria liquid was then prepared by anaerobically culturing the mixture at 37°C for 24 hours.
[0040] In a test tube, 30 μl of a 1.5% by weight aqueous solution of sodium cholate and the enterobacteria liquid (OD 600 value is 0.1; that is, the number of intestinal bacteria is 1.0 × 10 7 cfu) was added, and GAM liquid medium was then added so that the total volume in the test tube was 3 ml. Then, 40 mg of dried red koji rice powder (Example 1) or 40 mg of polished rice powder (Comparative Example 1) was added. Furthermore, 1 ml of liquid paraffin was added to the upper layer in the test tube, and anaerobic culture was carried out at 37°C for 48 hours. For comparison, culture was carried out under the same conditions as above, except that the dried red koji rice powder and polished rice powder were not added (Comparative Example 2).
[0041] After the culture was completed, the upper layer of liquid paraffin was discarded, and 500 μl of hexane was added to the test tube to remove any remaining liquid paraffin. Then, 1.5 ml of the contents of the test tube were collected and subjected to freeze-drying. 0.9 ml of distilled water and 0.5 ml of chloroform were added to the obtained freeze-dried product and stirred, and then 0.5 ml of chloroform was further added and stirred. Then, centrifugation (2300 rpm, 15 minutes) was performed to collect the upper layer. 200 μl of the obtained upper layer, 60 μl of an aqueous solution containing 0.02 wt% ribitol (external standard), and 800 μl of distilled water were added to a microtube and freeze-dried. 300 μl of methoxyamine was added to the obtained freeze-dried product and incubated for 90 minutes while stirring at 1500 rpm to obtain a sample for gas chromatography mass spectrometry (GC / MS). The obtained sample was subjected to gas chromatography mass spectrometry to measure the contents of succinic acid and lactic acid. For comparison, the amounts of succinic acid and lactic acid at the start of culture were also measured in the same manner when dried rice red koji powder was added.
[0042] 1-3. Measurement of butyric acid production by intestinal bacteria Feces from a 10-week-old male mouse (C57BL / 6) was inoculated onto GAM agar medium to culture the intestinal bacteria. Next, a loopful of the intestinal bacteria cultured on the agar medium was inoculated into a test tube containing 3 ml of YCFA liquid medium, and 1 ml of liquid paraffin was added to the top layer of the medium, followed by anaerobic culture at 37°C for 48 hours (preculture).
[0043] 30 mg (Example 2) or 100 mg (Example 3) of dried rice red yeast rice powder and 5 ml of YCFA liquid medium were added to a vial, and then nitrogen was injected into the vial, the lid was closed, and the vial was autoclaved. Next, 50 μl of an aqueous vitamin solution (containing 0.2 wt% biotin, 0.2 wt% folic acid, 1 wt% pyridoxine hydrochloride, 0.5 wt% thiamine hydrochloride hydrate, 0.5 wt% riboflavin, 0.5 wt% nicotinic acid, 0.5 wt% D-calcium pantothenate, 0.01 wt% vitamin B12, 0.5 wt% p-aminobenzoic acid, and 0.5 wt% DL-α-lipoic acid) was added to the vial. Separately, the culture solution (OD 600value is 0.1; that is, the number of intestinal bacteria is 1.0 × 10 7 cfu) were centrifuged to remove the supernatant, and 50 to 100 μl of YCFA liquid medium was added to the obtained bacterial cells to prepare an enterobacteria liquid. The entire amount of the obtained enterobacteria liquid was added to the above-mentioned vial, and anaerobic culture was performed at 37°C for 48 hours. For comparison, culture was performed under the same conditions as above, except that no powder of dried red rice koji was added (Comparative Example 3).
[0044] After the cultivation was completed, 1.5 ml of the contents of the vial was collected and freeze-dried. Using the freeze-dried product, a sample for GC / MS was prepared in the same manner as above, and the butyric acid content was measured by gas chromatography mass spectrometry. For comparison, the amount of butyric acid at the start of cultivation was also measured in the same manner under conditions where dried red rice koji powder was added.
[0045] 2. Test Results The results are shown in Tables 1 to 3. Tables 1 to 3 show the amount of each short-chain fatty acid produced, calculated as the ratio of the peak area of each short-chain fatty acid to the peak area of ribitol (external standard) measured by GC / MS. As a result, it was confirmed that the amounts of succinic acid, lactic acid, and butyric acid produced by intestinal bacteria increased in the presence of dried red rice koji powder, making it clear that rice koji and its processed products have the effect of promoting the production of short-chain fatty acids in the intestines.
[0046] [Table 1]
[0047] [Table 2]
[0048] [Table 3]
Claims
1. An agent for promoting the production of short-chain fatty acids in the intestines, comprising red koji or a processed product thereof.
2. The short-chain fatty acid production promoter according to claim 1 , wherein the red koji or a processed product thereof is produced using Monascus pilosus.
3. 3. The short-chain fatty acid production promoter according to claim 1 or 2, which is used to promote production in the intestine of at least one short-chain fatty acid selected from the group consisting of lactic acid, succinic acid, and butyric acid.
4. The short-chain fatty acid production promoter according to any one of claims 1 to 3, which is used by being added to food and drink, medicines for internal use, feed, or pet food.
Citation Information
Patent Citations
Promoter of production of lower fatty acid in intestine
JP2000143519A
Visceral fat accumulation inhibitor
JP2012158553A
Novel Lactobacillus sakei and compositions containing the same
JP2019528763A
Agent for promoting generation of short-chain fatty acids within intestinal canal
JP2021020871A
Use of a Material, Produced from Fungal Fermentation, as a Food Supplement
US20130011384A1
